KFP
SRPT icon

Keener Financial Planning’s Sarepta Therapeutics SRPT Stock Holding History

Keener Financial Planning’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26
Closed -$1K – 216
2025
Q1 		$1K Hold
26
– – ﹤0.01% 170
2024
Q4 		$3K Hold
26
– – ﹤0.01% 166
2024
Q3 		$3K Hold
26
– – ﹤0.01% 171
2024
Q2 		$4K Hold
26
– – ﹤0.01% 165
2024
Q1 		$4K Hold
26
– – ﹤0.01% 178
2023
Q4 		$3K Buy
+26
New +$2.49K ﹤0.01% 175

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Keener Financial Planning's SRPT Position: Q2 2025 in Review

Keener Financial Planning sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 26 shares — an estimated $1K sold.

Keener Financial Planning first reported a position in SRPT in Q4 2023 and held it in 6 quarters. The position peaked at $4K in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Keener Financial Planning reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Keener Financial Planning sold 26 Sarepta Therapeutics shares in Q2 2025, an estimated $1K.
  • Keener Financial Planning first reported a position in Sarepta Therapeutics in Q4 2023 and held it in 6 quarters.
  • Keener Financial Planning's Sarepta Therapeutics position peaked at $4K in Q2 2024.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Keener Financial Planning's 13F filing for Q2 2025, filed 25 Jul 2025.